Hepatic Arterial Infusion for Colorectal Liver Metastases

Guideline Objective

To make recommendations regarding the use of hepatic arterial infusion (HAI) in the treatment of patients with colorectal cancer (CRC) liver metastases with respect to overall survival, disease-free survival, progression-free survival (PFS), and hepatic PFS.  

Patient Population

These recommendations apply to adults with liver metastases from CRC.  

Intended Guideline Users

The intended users of this guideline are healthcare providers involved in the delivery of care of adults with liver metastases from CRC.  

Research Question(s)

This guidance document examined the evidence to answer the following questions:  

1. What is the benefit of the addition of HAI to ST in patients with resectable or resected CRC liver metastases with respect to OS, DFS, PFS, and hepatic PFS?  
2. What is the benefit of the addition of HAI to ST in first-line treatment in patients with unresectable CRC liver metastases with respect to OS, DFS, PFS, and hepatic PFS?   
3. What is the benefit of the addition of HAI with or without ST in second-line (or later) treatment of unresectable CRC liver metastases with respect to OS, DFS, PFS, and hepatic PFS?